Navigation Links
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
Date:5/15/2008

f hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern because of the aging of the population. Patients suffering from atrial fibrillation have twice the risk of death, an increased risk of stroke and cardiovascular complications, including congestive heart failure. Furthermore atrial fibrillation considerably impairs patients' lives, mainly because of their inability to perform normal daily activities due to complaints of palpitations, chest pain, dyspnoea, fatigue or light-headedness, without consideration of the cumbersome and sometime serious constraints imposed by current therapies of atrial fibrillation.

"In atrial fibrillation where treatment morbidity-mortality benefit still needed to be demonstrated, ATHENA is a unique trial using clinically relevant outcomes such as cardiovascular hospitalization or death as the primary endpoint. In this regard, the trial has clearly achieved these safety and efficacy endpoints," said Dr Stefan H. Hohnloser, J.W. from the Goethe University, Division of Clinical Electrophysiology, Frankfurt, Germany, who served as co-principal investigator of the ATHENA study. "As a consequence, dronedarone is the first potential treatment for atrial fibrillation, which was demonstrated in the ATHENA trial to reduce cardiovascular hospitalization or mortality in patients with AF," he added.

The most frequently reported adverse events of Multaq(R) vs. placebo induced gastro-intestinal effect (26% vs. 22%), skin disorder (10% vs. 8%, mainly rash) and increased blood creatinine (4.7% vs. 1%). The mechanism of blood creatinine increase (inhibition of creatinine secretion at the renal tubular level) was well defined, in a separate study of healthy volunteers. Multaq(R) showed a rate of pro-arrhythmia similar to placebo and no excess of hospitalizations for congestive heart failure. There was a s
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
2. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
3. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
4. Hospital Launches Landmark Emergency Medicine Project
5. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
6. Viatronix V3D-Colon Utilized in Another Landmark Study
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
11. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/27/2015)... and JERUSALEM , Feb. ... company developing octreotide capsules, its lead product for the ... $70 million Series E financing round. Participants in the ... Ventures, and an undisclosed blue chip public investment fund, ... 7 Med Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Finesse Solutions announced the expansion of its operations in ... planned for mid-March and access for customers is expected ... A-563, and located adjacent to the current office, the ... Finesse automation engineering team and allow Finesse to bring on ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3New Finesse Office in United Kingdom 2
... , THOUSAND OAKS, Calif., Nov. 30 Amgen ... present updated long-term safety and efficacy data for Nplate® (romiplostim) ... will present the first Nplate study in a pediatric setting ... the 2009 American Society of Hematology (ASH) Annual Meeting and ...
... , CHICAGO, Nov. 30 Middle-aged men and ... be unknowingly causing damage to their knees and increasing their ... the annual meeting of the Radiological Society of North America ... activity levels may be at greater risk for developing knee ...
Cached Medicine Technology:Amgen Highlights Data to be Presented at ASH 2Amgen Highlights Data to be Presented at ASH 3Amgen Highlights Data to be Presented at ASH 4Amgen Highlights Data to be Presented at ASH 5Amgen Highlights Data to be Presented at ASH 6Amgen Highlights Data to be Presented at ASH 7Amgen Highlights Data to be Presented at ASH 8Amgen Highlights Data to be Presented at ASH 9Amgen Highlights Data to be Presented at ASH 10Amgen Highlights Data to be Presented at ASH 11Too Much Physical Activity May Lead to Arthritis 2Too Much Physical Activity May Lead to Arthritis 3
(Date:3/1/2015)... Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... is approved to treat Overactive Bladder (OAB) symptoms, such as ... in adults when another type of medication (anticholinergic) does not ... a different treatment option that takes another approach to targeting ... , BOTOX® works on the nerves and bladder muscle, blocking ...
(Date:3/1/2015)... Ticket Down is a reputable source for ... Soldier Field. Deadheads have been anxiously anticipating this blockbuster ... Dead was formed 50 years ago back in the 60s ... until the untimely death of Jerry Garcia in 1995. ... blues, reggae, rock, bluegrass, folk, space rock and country to ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... In a recent episode of ... Game Change Athlete Development Services and Consultancy talks ... of athlete development and player engagement during and after ... that athletes face and how off-field activities are a ... became involved in athlete development issues while in graduate ...
(Date:2/28/2015)... Morristown, NJ (PRWEB) February 28, 2015 ... Month—is a good time to remind ourselves and ... be ignored, say Atlantic NeuroSurgical Specialists (ANS). , ... (TBI), which account for 75% of TBIs. There ... word concussion may sound benign, but it is ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
... announced,the European launch of its i.v.STATION Robot with a ... Spain [Booth 21,Level -1] next week. Health Robotics also ... world, and the simultaneous showcase of,CytoCare(TM), the world,s only ... its strategic partners (B|Braun, Booths C9-C12). , ...
... CareBETHESDA, Md., March 18 The Cystic Fibrosis Foundation ... leadership in improving the quality of care for people ... Quality Assurance (NCQA).The outlook for people with CF continues ... by the Foundation. In the 1950s, few children with ...
... FRANCISCO, March 18 Medivation, Inc. (Nasdaq: ... received written permission from the U.S. Food and ... 3 trial of MDV3100, its novel androgen receptor ... (CRPC) who have failed docetaxel-based chemotherapy. The ...
... be applied using inkjet printer technology, researchers say , , ... partners as marine mussels and printer inkjet technology, researchers ... be used with greater precision, promote faster recovery and ... used to join tissue together after a patient has ...
... consumption offers the most protection, study finds, , , WEDNESDAY, March ... have one or two glasses of beer or wine a ... heavy drinkers, a new study suggests. , Moderate drinking has ... it also has been linked to increasing the risk for ...
... Taps into Latino Market Underserved by other ... Systems, Inc. (OTC Bulletin Board: FVRL), which ... (collectively, "MMR") provides consumer-controlled Personal Health Records ... deposit box storage solutions ( www.myesafedepositbox.com ), ...
Cached Medicine News:Health News:Health Robotics Announces European Launch of i.v.STATION(TM) and Global List of 2009 Installations 2Health News:Health Robotics Announces European Launch of i.v.STATION(TM) and Global List of 2009 Installations 3Health News:Health Robotics Announces European Launch of i.v.STATION(TM) and Global List of 2009 Installations 4Health News:Cystic Fibrosis Foundation to Receive Prestigious Health Care Award 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:Mussel-Based Glue May Make Surgery Safer 2Health News:A Little Drink May Be Good for Your Bones 2Health News:A Little Drink May Be Good for Your Bones 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: